Dr. Matthew C. Ward on adjuvant radiotherapy in prostate cancer

"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Olaparib plus abiraterone and prednisone or prednisolone was granted FDA approval in May 2023 for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Data indicated that the test preferentially detected high-grade, clinically significant prostate cancer, with 93% of detected cancers being GG3-5 and 67% being stage 3 or 4.

“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.